MedTrace Logo

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

NCT06171113 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-04-01

No results posted yet for this study

Summary

The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.

Conditions

  • Malaria, Falciparum

Interventions

DRUG

GSK4024484C

Doses administrated orally with 240 mL of water.

DRUG

Placebo

Doses administrated orally with 240 mL of water.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2026-08-07
Completion
2026-08-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06171113 on ClinicalTrials.gov